William Stohl

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. pmc The discovery and development of belimumab: the anti-BLyS-lupus connection
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Nat Biotechnol 30:69-77. 2012
  2. doi Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus
    William Stohl
    University of Southern California Keck School of Medicine, Division of Rheumatology, 2011 Zonal Ave HMR 711, Los Angeles, CA 90033, USA 1 323 442 1959 1 323 442 2874
    Expert Opin Ther Targets 18:473-89. 2014
  3. doi Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study
    William Stohl
    Division of Rheumatology, Los Angeles County University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    J Rheumatol 40:579-89. 2013
  4. pmc Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
    William Stohl
    Division of Rheumatology, Los Angeles County and University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Ann Rheum Dis 71:1289-96. 2012
  5. doi Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033, USA
    Curr Rheumatol Rep 14:303-9. 2012
  6. pmc Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
    William Stohl
    Los Angeles County University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Arthritis Rheum 64:2328-37. 2012
  7. pmc Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
    Richard Furie
    Division of Rheumatology and Allergy Clinical Immunology, North Shore Long Island Jewish Health System, Marcus Avenue, Lake Success, New York 11042, USA
    Arthritis Res Ther 10:R109. 2008
  8. ncbi BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Curr Dir Autoimmun 8:289-304. 2005
  9. ncbi Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II
    William Stohl
    Division of Rheumatology and Immunology, Department of Medicine, University of Southern California Keck School of Medicine, 2001 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
    Clin Immunol 116:257-64. 2005
  10. ncbi BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles 90033, USA
    Arthritis Rheum 52:2080-91. 2005

Research Grants

  1. The vital role of BAFF in the development of SLE
    William Stohl; Fiscal Year: 2007
  2. The vital role of BAFF in the development of SLE
    William Stohl; Fiscal Year: 2010

Detail Information

Publications56

  1. pmc The discovery and development of belimumab: the anti-BLyS-lupus connection
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Nat Biotechnol 30:69-77. 2012
    ....
  2. doi Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus
    William Stohl
    University of Southern California Keck School of Medicine, Division of Rheumatology, 2011 Zonal Ave HMR 711, Los Angeles, CA 90033, USA 1 323 442 1959 1 323 442 2874
    Expert Opin Ther Targets 18:473-89. 2014
    ....
  3. doi Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study
    William Stohl
    Division of Rheumatology, Los Angeles County University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    J Rheumatol 40:579-89. 2013
    ..To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA)...
  4. pmc Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
    William Stohl
    Division of Rheumatology, Los Angeles County and University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Ann Rheum Dis 71:1289-96. 2012
    ..To determine the efficacy and safety of ocrelizumab (OCR) with methotrexate (MTX) in MTX-naive rheumatoid arthritis (RA) patients...
  5. doi Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033, USA
    Curr Rheumatol Rep 14:303-9. 2012
    ..Whether these differences will have meaningful consequences for efficacy and safety remains to be determined...
  6. pmc Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
    William Stohl
    Los Angeles County University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Arthritis Rheum 64:2328-37. 2012
    ....
  7. pmc Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
    Richard Furie
    Division of Rheumatology and Allergy Clinical Immunology, North Shore Long Island Jewish Health System, Marcus Avenue, Lake Success, New York 11042, USA
    Arthritis Res Ther 10:R109. 2008
    ....
  8. ncbi BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Curr Dir Autoimmun 8:289-304. 2005
    ..These features collectively point to BLyS and/or its receptors as attractive therapeutic targets in human SLE...
  9. ncbi Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II
    William Stohl
    Division of Rheumatology and Immunology, Department of Medicine, University of Southern California Keck School of Medicine, 2001 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
    Clin Immunol 116:257-64. 2005
    ..This raises the possibility that MHCII affects B cells in a manner that, at least in part, is independent of helper T cell function...
  10. ncbi BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles 90033, USA
    Arthritis Rheum 52:2080-91. 2005
    ..To determine whether overexpression of BAFF can accelerate the development of systemic lupus erythematosus-associated end-organ disease in hosts with an underlying autoimmune diathesis...
  11. ncbi B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?
    William Stohl
    Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, 2011 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
    Clin Immunol 121:1-12. 2006
    ..Among the systemic immune-based rheumatic disorders, we will focus on rheumatoid arthritis and systemic lupus erythematosus, two disorders for which therapeutic B cell targeting is being intensely investigated...
  12. ncbi Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases
    William Stohl
    Division of Rheumatology, University of Southern California, 2011 Zonal Ave HMR 711, Los Angeles, CA 90033, USA
    Endocr Metab Immune Disord Drug Targets 6:351-8. 2006
    ..These features collectively point to BLyS as an attractive therapeutic target in human rheumatic diseases...
  13. pmc Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity
    William Stohl
    Department of Medicine, Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    J Immunol 181:833-41. 2008
    ..These findings may help explain the limited clinical efficacy appreciated to date of BAFF antagonists in human SLE...
  14. pmc Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Arthritis Rheum 62:2432-42. 2010
    ..To determine whether overexpression of BAFF can promote systemic lupus erythematosus (SLE)-like autoimmunity in mice that are otherwise autoimmune-resistant...
  15. ncbi Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein
    William Stohl
    Division of Rheumatology, University of Southern California, Keck School of Medicine, Los Angeles 90033, USA
    Curr Opin Rheumatol 14:522-8. 2002
    ..By inference, BLyS protein may also play an important contributory role in pathogenesis and/or propagation of human SLE and becomes a legitimate candidate target for antagonist biologic agents...
  16. pmc Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus
    W Stohl
    Division of Rheumatology, Department of Medicine, Los Angeles County University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Ann Rheum Dis 63:1096-103. 2004
    ....
  17. ncbi Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90333, USA
    Arthritis Rheum 50:2227-39. 2004
    ..To assess the effects of altered class II major histocompatibility complex (MHCII) expression on circulating autoantibody levels in C57BL/6 (B6) mice congenic for the Sle1 (B6.Sle1 mice) or Nba2 (B6.Nba2 mice) regions...
  18. ncbi B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases
    William Stohl
    University of Southern California Keck School of Medicine, Division of Rheumatology, 2011 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
    Curr Rheumatol Rep 4:345-50. 2002
    ..In addition, it may play a similar role in other systemic immune-based rheumatic diseases, and becomes a legitimate candidate target for antagonist biologic agents...
  19. ncbi B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients
    William Stohl
    Division of Rheumatology, Department of Medicine, Los Angeles County, Los Angeles, CA, USA
    Clin Immunol 104:115-22. 2002
    ..This raises the possibility that the combination of a BLyS protein antagonist with an agent that targets (helper) T cells may have salutary synergistic effects on autoantibody production in diseases such as systemic lupus erythematosus...
  20. ncbi Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA
    Expert Opin Ther Targets 8:177-89. 2004
    ..Results from a Phase I clinical trial with a BLyS antagonist in human SLE have shown the antagonist to be biologically active and safe. These features collectively point to BLyS as an attractive therapeutic target in human disease...
  21. pmc SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
    William Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Arthritis Res Ther 5:136-8. 2003
    ....
  22. ncbi B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations
    William Stohl
    Los Angeles County University of Southern California Medical Center, and University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Arthritis Rheum 48:3475-86. 2003
    ..To assess the overexpression of B lymphocyte stimulator (BLyS) over time in patients with systemic lupus erythematosus (SLE)...
  23. ncbi A therapeutic role for BLyS antagonists
    W Stohl
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles 90033, USA
    Lupus 13:317-22. 2004
    ..These features collectively point to BLyS as an attractive therapeutic target in human disease...
  24. ncbi MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4)
    William Stohl
    Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Int Immunol 16:895-904. 2004
    ....
  25. pmc Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF
    Chaim O Jacob
    Department of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, Los Angeles, CA 90033, USA
    J Immunol 177:2671-80. 2006
    ..These observations may have profound ramifications for the use of BAFF antagonists in human SLE and related diseases...
  26. pmc Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway
    Noam Jacob
    Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    J Immunol 182:2532-41. 2009
    ....
  27. pmc Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice
    Chaim O Jacob
    University of Southern California, Keck School of Medicine, Los Angeles, USA
    Arthritis Rheum 64:1610-9. 2012
    ..To determine the role of APRIL in the development of systemic lupus erythematosus (SLE) in mice...
  28. pmc B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice
    Noam Jacob
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    J Immunol 186:4984-93. 2011
    ..Moreover, our results document important biological differences between IFN-α-driven and spontaneous natural SLE disease...
  29. pmc A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
    Daniel J Wallace
    Cedars Sinai Medical Center, University of California, Los Angeles, USA
    Arthritis Rheum 61:1168-78. 2009
    ..To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE)...
  30. pmc Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor
    Chaim O Jacob
    University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Arthritis Rheum 65:1043-54. 2013
    ..To determine the necessity for any individual BAFF receptor in the development of systemic lupus erythematosus (SLE)...
  31. doi Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus
    Ellen M Ginzler
    From the State University of New York SUNY Downstate Medical Center, Brooklyn, New York Cedars Sinai Medical Center David Geffen School of Medicine at the University of California at Los Angeles Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma North Shore Long Island Jewish Health System, Lake Success, New York Los Angeles County University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California University of Alabama at Birmingham, Alabama MedStar Washington Hospital Center, Washington, DC Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma University of Michigan, Ann Arbor, Michigan Human Genome Sciences Inc, Rockville Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Rheumatol 41:300-9. 2014
    ..To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n = 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 currently ongoing)...
  32. ncbi In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens
    Kyoung Soo Kim
    University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    Clin Immunol 108:182-9. 2003
    ..In hosts who have lost tolerance to self Ag, chronic exposure to SAg may preferentially promote expansion of autoreactive T cells and facilitate development of clinical disease...
  33. ncbi Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis
    Soon Min Tan
    Los Angeles County University of Southern California Medical Center, 90033, USA
    Arthritis Rheum 48:982-92. 2003
    ..To determine whether synovial fluid (SF) levels and cell-surface expression of B lymphocyte stimulator (BLyS) protein and SF levels of APRIL are elevated in patients with inflammatory arthritis (IA)...
  34. ncbi TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells
    Song Guo Zheng
    Division of Rheumatology and Immunology, Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Immunol 176:3321-9. 2006
    ..Although natural CD4+CD25+ cells develop normally in CTLA-4(-/-) mice, the lack of TGF-beta-induced, peripheral CD4+CD25+ suppressor cells in these mice may contribute to their rapid demise...
  35. pmc B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
    Christopher E Collins
    Division of Rheumatology, Department of Medicine, Los Angeles County University of Southern California Medical Center, Los Angeles, CA 90033, USA
    Arthritis Res Ther 8:R6. 2006
    ..BLyS mRNA levels may be a helpful biomarker in the clinical monitoring of SLE patients...
  36. pmc Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future
    Noam Jacob
    Division of Rheumatology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Autoimmunity 43:84-97. 2010
    ..With these points in mind, this review will focus on the autoantibody-dependent and autoantibody-independent roles for B cells in SLE and on therapeutic approaches that target B cells...
  37. doi Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD 21205, USA
    Arthritis Rheum 58:2453-9. 2008
    ..To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE)...
  38. pmc Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study
    Noa Schwartz
    Division of Rheumatology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Arthritis Res Ther 11:R143. 2009
    ..Evidence for the importance of TWEAK in the pathogenesis of lupus nephritis (LN) has been recently introduced. Thus, TWEAK levels may serve as an indication of LN presence and activity...
  39. pmc BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis
    Xiaohui Zhou
    Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America
    PLoS ONE 6:e23629. 2011
    ..BAFF, in addition to promoting B cell survival and differentiation, may affect T cells. The objective of this study was to determine the effect of BAFF on Th17 cell generation and its ramifications for the Th17 cell-driven disease, EAE...
  40. pmc Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside
    William Stohl
    Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Curr Opin Rheumatol 23:305-10. 2011
    ..Several agents that target BLyS are in clinical trials now, and we summarize recent results here, with a focus on systemic lupus erythematosus (SLE)...
  41. ncbi New and promising treatments for rheumatoid arthritis
    R John Looney
    Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA
    Am J Orthop (Belle Mead NJ) 36:18-23. 2007
  42. ncbi In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4(+) cells and human MHC class II
    W Stohl
    Division of Rheumatology and Immunology, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033, USA
    Int Immunol 13:1291-300. 2001
    ..This model system may be useful in investigating the polyclonally activating effects of microbial products (prototypic environmental insults) on the development of systemic autoimmunity...
  43. ncbi Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells
    W Stohl
    Department of Medicine, University of Southern California, Los Angeles 90033, USA
    J Immunol 161:3292-8. 1998
    ..This finding may help explain why clinical autoimmunity associated with increased titers of autoantibodies is a predominant feature of defects in CD95 or CD95 ligand...
  44. ncbi CD95 (Fas)-based, superantigen-dependent, CD4+ T cell-mediated down-regulation of human in vitro immunoglobulin responses
    W Stohl
    Department of Medicine, University of Southern California, Los Angeles 90033, USA
    J Immunol 160:5231-8. 1998
    ..Defects in SAg-based down-regulation may contribute to autoimmune disorders such as SLE...
  45. doi Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells
    Ning Kong
    Rheumatology Division, University of Southern California, Los Angeles, California 90033, USA
    Ann Rheum Dis 71:1567-72. 2012
    ..Although natural regulatory T cells (nTregs) can suppress osteoclastogenesis, the role of TGF-β-induced CD4+Foxp3+ Tregs (iTregs) in osteoclastogenesis remains unknown...
  46. doi B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients
    Sandy D Hong
    Childrens Hospital Los Angeles, Los Angeles, CA 90033, USA
    Arthritis Rheum 60:3400-9. 2009
    ..To assess the expression of B lymphocyte stimulator (BLyS) in patients with pediatric systemic lupus erythematosus (SLE) or juvenile idiopathic arthritis (JIA)...
  47. ncbi Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases
    G S Cheema
    Los Angeles County + University of Southern California Medical Center, University of Southern California, 90033, USA
    Arthritis Rheum 44:1313-9. 2001
    ..Local production of BLyS in the joints may contribute to joint pathology. Patients with elevated serum BLyS levels may be ideal candidates for therapeutic targeting of BLyS...
  48. ncbi Increased CXCL8 (IL-8) expression in Multiple Sclerosis
    Brett T Lund
    Department of Neurology, Keck School of Medicine, University of Southern California, MCH 142, Los Angeles, California 90033, USA
    J Neuroimmunol 155:161-71. 2004
    ..We suggest that CXCL8 may serve as a marker of monocyte activity in MS and may play a role in monocyte recruitment to the CNS...
  49. pmc Cytokine disturbances in systemic lupus erythematosus
    Noam Jacob
    Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, 2011 Zonal Ave, HMR 711, Los Angeles, CA 90033, USA
    Arthritis Res Ther 13:228. 2011
    ..The present review will examine the roles of each of these cytokines in murine and human SLE, and will summarize results from clinical trials of agents that target these cytokines...
  50. doi Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis
    C E Collins
    Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Ann Rheum Dis 68:1768-74. 2009
    ..To determine whether synovial expression of triggering receptor expressed on myeloid cells 1 (TREM-1) is upregulated in patients with distinct types of inflammatory or non-inflammatory arthritis...
  51. ncbi Cell cycle phase-specific survival of CD95 ligand-challenged Jurkat cells: upregulation of heat-shock response
    T B Parr
    Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine, University of California, Los Angeles, 90033, USA
    Cell Immunol 211:21-9. 2001
    ....
  52. ncbi B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders
    D T La
    Division of Rheumatology, Department of Medicine, Los Angeles County and University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Ann Rheum Dis 67:1132-8. 2008
    ..To assess the effects of tumour necrosis factor (TNF) antagonist therapy on B lymphocyte stimulator (BLyS) expression in patients with rheumatoid arthritis (RA)...
  53. ncbi BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases
    Viktor Roschke
    Department of Antibody Development, Human Genome Sciences, 9410 Key West Avenue, Rockville, MD 20850, USA
    J Immunol 169:4314-21. 2002
    ..These findings raise the possibility that active BLyS/APRIL heterotrimers may play a role in rheumatic and other autoimmune diseases and that other members of the TNF ligand superfamily may also form active soluble heterotrimers...
  54. ncbi Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse
    Geraldine Cambridge
    University College London, London, UK
    Arthritis Rheum 54:723-32. 2006
    ....
  55. ncbi Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI)
    Monica Schaller
    Department of Immunology, IMM2, The Scripps Research Institute, La Jolla, CA 92037, USA
    Biochem Biophys Res Commun 349:838-45. 2006
    ..This, in turn, may trigger production of proinflammatory cytokines and perpetuate the inflammatory process...

Research Grants5

  1. The vital role of BAFF in the development of SLE
    William Stohl; Fiscal Year: 2007
    ....
  2. The vital role of BAFF in the development of SLE
    William Stohl; Fiscal Year: 2010
    ..abstract_text> ..